Crearene – the human dimension in dialysis treatments
Crearene AG is a pioneering patient-centric medical technology company. Our mission is to enhance the quality of life of dialysis patients. Our goal is to reduce co-morbidities such as mental fatigue, including loss of memory and learning functions, depressions, physical weakness, anaemia, cardiovascular conditions, or compromised immune systems.
Crearene’s technology can have a transformational impact on the dialysis landscape. The technology may enable hundreds of thousands of current chronic dialysis patients to significantly if not dramatically improve their quality of life.
The company is headquartered in Switzerland with offices in Frauenfeld, Thurgau.
Three Questions
Theo Wallimann dedicated most of his research life as a research group leader and Adjunct Professor at the Dept. of Biology at the ETH Zurich, Switzerland, to the elucidation of the molecular structure, function and physiology of Creatine Kinases.
After Linford Christie won his Olympic gold medal in the 100m sprint in 1992 in Barcelona, Creatine attracted a lot of attention as a nutritional supplement for sports, improving muscle bioenergetics. From then on, the pleiotropic effects of Creatine for cell and organ protection became an additional research topic of the Wallimann group at the ETH-Zurich. Together with a nephrologist friend, Theo Wallimann elaborated international patents for “Intra-dialytic Creatine supplementation of dialysis patients to improve their health and quality of life“. It is an unforeseen gift for a basic researcher to see how some of his work may become beneficial for patients, at last.
https://mhs.biol.ethz.ch/about-us/emeriti-formermembers/wallimann.html
